AIT Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

REHOVOT, Israel and NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC: AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), today announced that Steve Lisi, Chief Executive Officer, will provide a corporate overview at the Ladenburg Thalmann 2017 Healthcare Conference, taking place September 26, 2017 at the Sofitel Hotel New York.

About AIT Therapeutics Inc.AIT Therapeutics Inc. is a clinical-stage anti-microbial therapeutic company developing novel non-antibiotic anti-microbial therapeutics for respiratory diseases based on nitric oxide (NO) as well as other indications. The Company is applying its therapeutic expertise to prevent and treat lower respiratory tract infections, many of which cannot effectively be addressed with current standards of care. AIT Therapeutics is advancing its revolutionary respiratory targeted system in a pipeline of clinical trials for the treatment of bronchiolitis (RSV) exacerbations, and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.

CONTACT Steven LisiChief Executive OfficerAIT Therapeutics, Inc. [email protected]

Bob YedidLifeSci Advisors, LLC[email protected](646) 597 6989

You May Also Be Interested In

• QILEE Launches Containerized Modular Integrated Wastewater Treatment System in South Africa
• Chasing Mulan: Three Encounters with "Mulan"
• BNB Price Prediction Hits $840 October Target While Pepeto Presale Offers Traders a Bigger Setup